Clinical Trials Logo

Clinical Trial Summary

This study is a multi-center, non-interventional retrospective medical records review. The study will involve identification of medical records of patients with confirmed locally advanced unresectable or metastatic ES, who initiated systemic therapy between January 1, 2000 and December 31, 2017. Data for the chart review will be extracted retrospectively from eligible subjects' charts (electronic or paper). Information on prior surgical treatment and neoadjuvant/adjuvant therapies for ES will also be collected for ineligible subjects with a locally advanced or metastatic ES diagnosis who did not initiated systemic therapy. Data collected will be anonymized by the investigators and will not be traceable back to individual subjects by the sponsor (i.e., no protected health information [PHI] will be collected).


Clinical Trial Description

The sampling period will span from January 1, 2000 to December 31, 2017. As the chart abstraction dates may be different across institutions due to contracting and other logistical issues, to avoid seeing biased outcomes that may be related to this type of heterogeneity, a consistent study end date will be imposed for all patients when conducting the analysis. Information before this study end date will be analyzed and used to conduct the analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03837678
Study type Observational
Source Ipsen
Contact
Status Completed
Phase
Start date June 4, 2018
Completion date September 2, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT05286801 - Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Phase 1/Phase 2
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Active, not recruiting NCT03069378 - A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Phase 2
Active, not recruiting NCT02180867 - Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Phase 2/Phase 3
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Completed NCT02584309 - Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Not yet recruiting NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Phase 2
Completed NCT02601950 - A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Phase 2
Completed NCT03190174 - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Phase 1/Phase 2
Recruiting NCT03099681 - An Observational Study on Epithelioid Sarcoma
Recruiting NCT04416568 - Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Phase 2
Recruiting NCT05407441 - Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Phase 1/Phase 2
Recruiting NCT03967834 - Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group N/A
No longer available NCT04225429 - Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma